Home › Funds › Reynders McVeigh Capital Management, LLC › ABT

Reynders McVeigh Capital Management, LLC position in ABT

ABBOTT LABORATORIES · Health Care

Reynders McVeigh Capital Management, LLC reported holding 424,056 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$41.9M, representing 1.82% of its reported portfolio and ranking #17 among its reported holdings. Reynders McVeigh Capital Management, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)424.06K sh
Reported value held$41.91M
Portfolio Weight1.82%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Reynders McVeigh Capital Management, LLC's ABT position evolved

Reynders McVeigh Capital Management, LLC first disclosed a stake in ABT in Q3 2023 at 387,457 shares (US$37.5M). The position peaked in Q3 2025 at 419,036 shares, worth US$56.1M. Across 13 filings, Reynders McVeigh Capital Management, LLC increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 424,056 shares valued at US$41.9M — an increase of 8,821 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 387.46K $37.52M New
Q4 2023 385.96K $42.48M Hold
Q1 2024 396.18K $45.03M Add
Q2 2024 401.70K $41.74M Add
Q3 2024 406.72K $46.37M Add
Q4 2024 409.69K $46.34M Add
Q1 2025 409.56K $54.33M Hold
Q2 2025 406.63K $55.31M Reduce
Q3 2025 419.04K $56.13M Add
Q4 2025 419.86K $52.60M Hold
Q1 2026 421.66K $43.29M Hold
Q2 2026 415.24K $37.68M Reduce
Q3 2026 424.06K $41.91M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Reynders McVeigh Capital Management, LLC held ABT?

Reynders McVeigh Capital Management, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Reynders McVeigh Capital Management, LLC's current position in ABT?

As of Q3 2026, Reynders McVeigh Capital Management, LLC holds 424.06K shares of ABT (ABBOTT LABORATORIES), valued at $41.91M, representing 1.82% of its reported portfolio and ranking #17.

Has Reynders McVeigh Capital Management, LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Reynders McVeigh Capital Management, LLC increased its position in ABT. The position peaked in Q3 2025 at 419.04K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.